Publication | Closed Access

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom

Breast OncologyMedicineCancer ManagementBreast CancerUnited KingdomCancer TreatmentOncologyRadiation OncologyOsteoporosisOrthopaedic SurgeryIv Pamidronate